New Warnings Required for Gadolinium-Based Contrast Agents

Share this article:

The FDA is requiring that gadolinium-based contrast agents (GBCAs) carry new warnings on their labels about the risk of nephrogenic systemic fibrosis (NSF) if administered to certain patients with kidney disease.

Three GBCAs—Magnevist, Omniscan, and Optimark—will be described as inappropriate for use among patients with acute kidney injury or chronic severe kidney disease, according to the FDA. All GBCA labels will emphasize the need to screen patients to detect these types of kidney problems prior to administration.

NSF is a condition involving the formation of excess fibrous connective tissue in the skin, joints, eyes, and internal organs. Symptoms can include scaling, hardening and tightening of the skin, red or dark patches on the skin, and stiffness. NSF can lead to death, particularly if it involves organs, the FDA said.

Share this article:
You must be a registered member of RUN to post a comment.
close

Next Article in Acute Kidney Injury

More in Acute Kidney Injury

Dialysis and Low Creatinine a Bad Combo in AKI

Dialysis and Low Creatinine a Bad Combo in ...

In-hospital death risk is increased, a new study found.

AKI Predictors in Lymphoma Patients Identified

AKI Predictors in Lymphoma Patients Identified

Sepsis and diuretic and aminoglycoside use are among the factors associated with an increased risk of acute kidney injury.

Infectious Disease-Related AKI Characterized

Infectious Disease-Related AKI Characterized

Mortality rate is high, especially among patients with HIV/AIDS.